4074 related articles for article (PubMed ID: 27870103)
1. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
3. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
4. Hematologic Malignancies: Plasma Cell Disorders.
Dhodapkar MV; Borrello I; Cohen AD; Stadtmauer EA
Am Soc Clin Oncol Educ Book; 2017; 37():561-568. PubMed ID: 28561703
[TBL] [Abstract][Full Text] [Related]
5. How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma.
Cohen AD; Raje N; Fowler JA; Mezzi K; Scott EC; Dhodapkar MV
Clin Cancer Res; 2020 Apr; 26(7):1541-1554. PubMed ID: 31672768
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies as an addition to current myeloma therapy strategies.
Jullien M; Touzeau C; Moreau P
Expert Rev Anticancer Ther; 2021 Jan; 21(1):33-43. PubMed ID: 33052750
[TBL] [Abstract][Full Text] [Related]
7. CD38 as an immunotherapeutic target in multiple myeloma.
Bonello F; D'Agostino M; Moscvin M; Cerrato C; Boccadoro M; Gay F
Expert Opin Biol Ther; 2018 Dec; 18(12):1209-1221. PubMed ID: 30394809
[TBL] [Abstract][Full Text] [Related]
8. Immunopathogenesis and immunotherapy of multiple myeloma.
Tamura H
Int J Hematol; 2018 Mar; 107(3):278-285. PubMed ID: 29368256
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for the treatment of multiple myeloma.
Jung SH; Lee HJ; Vo MC; Kim HJ; Lee JJ
Crit Rev Oncol Hematol; 2017 Mar; 111():87-93. PubMed ID: 28259300
[TBL] [Abstract][Full Text] [Related]
10. Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.
Varga C; Laubach JP; Anderson KC; Richardson PG
Br J Haematol; 2018 May; 181(4):433-446. PubMed ID: 29748955
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Bone Marrow Microenvironment.
Moschetta M; Kawano Y; Podar K
Cancer Treat Res; 2016; 169():63-102. PubMed ID: 27696259
[TBL] [Abstract][Full Text] [Related]
12. Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors.
Gay F; D'Agostino M; Giaccone L; Genuardi M; Festuccia M; Boccadoro M; Bruno B
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):471-478. PubMed ID: 28689001
[TBL] [Abstract][Full Text] [Related]
13. Advances in immunotherapy in multiple myeloma.
Boussi L; Niesvizky R
Curr Opin Oncol; 2017 Nov; 29(6):460-466. PubMed ID: 28877078
[TBL] [Abstract][Full Text] [Related]
14. Advances and practical use of monoclonal antibodies in multiple myeloma therapy.
Lee HC; Weber DM
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):512-520. PubMed ID: 27913523
[TBL] [Abstract][Full Text] [Related]
15. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
Tai YT; Cho SF; Anderson KC
Front Immunol; 2018; 9():1822. PubMed ID: 30147691
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory effects of CD38-targeting antibodies.
van de Donk NWCJ
Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
[TBL] [Abstract][Full Text] [Related]
17. Immune therapy in multiple myeloma.
Luptakova K; Avigan D
Clin Adv Hematol Oncol; 2015 Nov; 13(11):767-75. PubMed ID: 27058703
[TBL] [Abstract][Full Text] [Related]
18. Myeloma: next generation immunotherapy.
Cohen AD
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):266-272. PubMed ID: 31808859
[TBL] [Abstract][Full Text] [Related]
19. Immunologic approaches for the treatment of multiple myeloma.
Rasche L; Weinhold N; Morgan GJ; van Rhee F; Davies FE
Cancer Treat Rev; 2017 Apr; 55():190-199. PubMed ID: 28431262
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
Afifi S; Michael A; Lesokhin A
Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
